Embryonic hematopoietic stem and progenitor cells show differential susceptibility to leukemic transformation upon acquisition of JMML-associated KrasG12D mutation

Juvenile myelomonocytic leukemia (JMML) is a rare, clinically heterogeneus myeloproliferative neoplasm of early childhood, caused by a mutation in the RAS pathway. One of the most significant challenges in JMML research is the difficulty of developing experimental models that faithfully recapitulate its pathogenesis. This challenge may stem from the critical importance of the cellular context in which JMML-driving mutations occur, especially considering that this hematological neoplasm has a prenatal origin in nearly half of the cases.